Sign in

    Maneka Mirchandaney

    former Director and Biotech Analyst at Evercore ISI

    Maneka Mirchandaney is a former Director and Biotech Analyst at Evercore ISI, specializing in biotechnology and healthcare sector research with a focus on companies such as Solid Biosciences. During her tenure at Evercore ISI, she recorded a 28.57% success rate and held an average return of -28.86% from her public ratings, based on seven tracked recommendations. Mirchandaney began her career following dual degrees in cognitive neuroscience and finance at the University of Pennsylvania, joining Evercore ISI before moving to Viking Global as Principal in 2022. She holds a magna cum laude distinction and comprehensive expertise in life sciences and finance, with her professional background reflecting a strong analytical skillset in healthcare equity research.

    Maneka Mirchandaney's questions to Solid Biosciences (SLDB) leadership

    Maneka Mirchandaney's questions to Solid Biosciences (SLDB) leadership • Q1 2021

    Question

    Maneka Mirchandaney of Evercore ISI asked whether the company is considering additional changes to the clinical protocol to further mitigate the risk of inflammatory events, such as adjusting the immunosuppressive drug regimen, based on the experience with Patient 8.

    Answer

    Acting Chief Medical Officer Dr. Cathryn Clary responded that ensuring patient safety is the top priority and that the team is actively investigating the event to determine how to best modify the risk mitigation profile. She confirmed they are exploring various options, including potential changes to dosing, but could not specify details while the investigation is ongoing with internal and external experts. Any changes would require DSMB and FDA approval.

    Ask Fintool Equity Research AI